Beam Therapeutics (BEAM) Projected to Release Earnings on Tuesday

Beam Therapeutics (NASDAQ:BEAM) is anticipated to issue its Q3 2026 results before the market opens on Tuesday, November 3rd. Analysts expect Beam Therapeutics to announce earnings of ($1.15) per share and revenue of $8.75 million for the quarter. Parties can find conference call details on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 9:30 AM ET.

Beam Therapeutics (NASDAQ:BEAM) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($1.18) EPS for the quarter, missing the consensus estimate of ($1.11) by ($0.07). The firm had revenue of $0.49 million for the quarter, compared to the consensus estimate of $16.37 million. Beam Therapeutics had a negative net margin of 54.75% and a negative return on equity of 30.71%. The firm’s revenue for the quarter was down 94.2% on a year-over-year basis. During the same quarter in the previous year, the business earned ($1.00) earnings per share. On average, analysts expect Beam Therapeutics to post ($4.49) EPS for the current fiscal year and ($5.05) EPS for the next fiscal year.

Beam Therapeutics Price Performance

Shares of BEAM stock opened at $23.79 on Tuesday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 14.57 and a current ratio of 14.57. Beam Therapeutics has a one year low of $20.23 and a one year high of $38.26. The company’s fifty day moving average price is $25.96 and its 200-day moving average price is $28.23.

Insider Activity at Beam Therapeutics

In other news, CEO John Evans sold 25,000 shares of the firm’s stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $23.57, for a total transaction of $589,250.00. Following the completion of the transaction, the chief executive officer owned 1,047,205 shares in the company, valued at $24,682,621.85. This trade represents a 2.33% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 3.80% of the stock is owned by company insiders.

Analysts Set New Price Targets

BEAM has been the subject of a number of analyst reports. William Blair upgraded Beam Therapeutics to a “strong-buy” rating in a research note on Wednesday, September 23rd. HC Wainwright restated a “buy” rating and issued a $80.00 price objective on shares of Beam Therapeutics in a research report on Thursday, October 15th. Wall Street Zen raised Beam Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, October 3rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Beam Therapeutics in a research report on Thursday, October 15th. Finally, Wedbush reiterated an “outperform” rating and set a $65.00 target price on shares of Beam Therapeutics in a research report on Wednesday, October 14th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Beam Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $50.10.

About Beam Therapeutics

Beam Therapeutics Inc is a biotechnology company developing precision genetic medicines for patients with serious diseases. The company’s platform uses base editing, a form of gene editing designed to make targeted changes to individual DNA letters without creating double-strand breaks. Beam is also advancing related editing technologies and delivery systems intended to improve the precision and effectiveness of genetic treatments.

Beam’s pipeline includes investigational programs for diseases such as sickle cell disease, beta thalassemia, alpha-1 antitrypsin deficiency and glycogen storage disease type Ia.